Pro-survival role of MITF in melanoma

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 352-358

  Hartman, Mariusz L ^a   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; B RAF KINASE; BCL2 RELATED PROTEIN A1; BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 2; ENDOTHELIN RECEPTOR; FAS LIGAND; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX3; VASCULOTROPIN; BCL2-RELATED PROTEIN A1; MITF PROTEIN, HUMAN; PROTEIN BCL 2; SCATTER FACTOR RECEPTOR;

APOPTOSIS; BIOLOGICAL FUNCTIONS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLINICAL TRIAL (TOPIC); ENZYME ACTIVE SITE; GENE TARGETING; HUMAN; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ULTRAVIOLET RADIATION; UPREGULATION; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR;

APOPTOSIS; CELL SURVIVAL; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MET; SKIN NEOPLASMS;

EID: 84925377770     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.319     Document Type: Review

References (109)

1. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400-14
2. Bell RE, Khaled M, Netanely D et al. (2014) Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol 134:441-51
3. Bell RE, Levy C (2011) The three m's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res 24:1088-106
4. Bemis LT, Chen R, Amato CM et al. (2008) MicroRNA-137 targets micro-phthalmia-associated transcription factor in melanoma cell lines. Cancer Res 68:1362-8
5. Bertolotto C, Lesueur F, Giuliano S et al. (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480:94-8
6. Beuret L, Flori E, Denoyelle C et al. (2007) Up-regulation of MET expression by α-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem 282:14140-7
7. Beuret L, Ohanna M, Strub T et al. (2011) BRCA1 is a new MITF target gene. Pigment Cell Melanoma Res 24:725-7
8. Boyle GM, Woods SL, Bonazzi VF et al. (2011) Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 24:525-37
9. Braeuer RR, Watson IR, Wu CJ et al. (2014) Why is melanoma so metastatic? Pigment Cell Melanoma Res 1:19-36
10. Busca R, Berra E, Gaggioli C et al. (2005) Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59
11. Cip1 expression to regulate cell cycle progression. Nature 433:764-9
12. Carreira S, Goodall J, Denat L et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 20:3426-39
13. Chattopadhyay C, Grimm EA, Woodman SE (2014) Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cells growth and migration. PLoS One 9:e83957
14. Cheli Y, Giuliano S, Fenouille N et al. (2012) Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 31:2461-70
15. Chen H, Weng QY, Fisher DE (2014) UV signaling pathways within the skin. J Invest Dermatol 134:2080-5
16. Chetoui N, Sylla K, Gagnon-Houde JV et al. (2008) Down-regulation of Mcl-1 by small interfering RNA sensitizes resistant melanoma cells to Fas-mediated apoptosis. Mol Cancer Res 6:42-52
17. Choi W, Miyamura Y, Wolber R et al. (2010) Regulation of human skin pigmentation in situ by repetitive UV exposure: molecular characterization of responses to UVA and/or UVB. J Invest Dermatol 130:1685-96
18. Cronin JC, Wunderlich J, Loftus SK et al. (2009) Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 22:435-44
19. Curtin NJ (2012) DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801-17
20. Del Bello B, Valentini MA, Zunino F et al. (2001) Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 20:4591-5
21. Denat L, Kadekaro AL, Marrot L et al. (2014) Melanocytes as instigators and victims of oxidative stress. J Invest Dermatol 134:1512-8
22. Denecker G, Vandamme N, Akay O et al. (2014) Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 21:1250-61
23. Dynek JN, Chan SM, Liu J et al. (2008) Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res 68:3124-32
24. Eccles MR, He S, Ahn A et al. (2013) MITF and PAX3 play distinct roles in melanoma cell migration; outline of a "genetic switch" theory involving MITF and PAX3 in proliferative and invasive phenotypes of melanoma. Front Oncol 3:229
25. Eichhoff OM, Weeraratna A, Zipser MC et al. (2011) Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 24:631-42
26. Feige E, Yokoyama S, Levy C et al. (2011) Hypoxia-mediated transcriptional repression of the melanoma-associated oncogene MITF. Proc Natl Acad Sci USA 108:E924-33
27. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61
28. Gajos-Michniewicz A, Duechler M, Czyz M (2014) MiRNA in melanoma-derived exosomes. Cancer Lett 347:29-37
29. Garraway LA, Widlund HR, Rubin MA et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22
30. Genovese G, Ghosh P, Li H et al. (2012) The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells. Cell Cycle 11:2206-15
31. Giuliano S, Ohanna M, Ballotti R et al. (2011) Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res 24:295-308
32. Goding CR (2011) A picture of Mitf in melanoma immortality. Oncogene 30:2304-6
33. Goodall J, Carreira S, Denat L et al. (2008) Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68:7788-94
34. Haflidadóttir BS, Bergsteinsdottir K, Praetorius C et al. (2010) miR-148 regulates Mitf in melanoma cells. PLoS One 5:e11574
35. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-74
36. Haq R, Fisher DE (2011) Biological and clinical relevance of the microphthalmia family of transcription factors in human cancer. J Clin Oncol 29:3474-82
37. Haq R, Fisher DE (2013) Targeting melanoma by small molecules: challenges ahead. Pigment Cell Melanoma Res 26:464-9
38. Haq R, Yokoyama S, Hawryluk EB et al. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110:4321-6
39. Harbst K, Lauss M, Cirenajwis H et al. (2014) Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 233:39-50
40. Hartman ML, Czyz M (2012) Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. Anticancer Agents Med Chem 12:966-81
41. Hartman ML, Czyz M (2013) Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331:24-34
42. Hartman ML, Talar B, Noman MZ et al. (2014) Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One 9:e95157
43. Hartsough E, Shao Y, Aplin AE (2014) Resistance to RAF inhibitors revisited. J Invest Dermatol 134:319-25
44. Hellwig CT, Passante E, Rehm M (2011) The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. Curr Mol Med 11:31-47
45. Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23:746-59
46. Hoek KS, Schlegel NC, Eichhoff OM et al. (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21:665-76
47. Jane-Valbuena J, Widlund HR, Perner S et al. (2010) An oncogenic role for ETV1 in melanoma. Cancer Res 70:2075-84
48. Johannessen CM, Johnson LA, Piccioni F et al. (2013) A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504:138-42
49. Kaneko T, Zhang Z, Mantellini MG et al. (2007) Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 67:9685-93
50. Kankuri E, Cholujova D, Comajova D et al. (2005) Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res 65:9914-22
51. Keenen B, Qi H, Saladi SV et al. (2010) Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene 29:81-92
52. Koludrovic D, Davidson I (2013) MITF, the Janus transcription factor of melanoma. Future Oncol 9:235-44
53. Kucharczak JF, Simmons MJ, Duckett CS et al. (2005) Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ 12:1225-39
54. Larribere L, Hilmi C, Khaled M et al. (2005) The cleavage of micro-phthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 19:1980-5
55. Lazar I, Perlman R, Lotem M et al. (2012) The clinical effect of the inhibitor of apoptosis protein livin in melanoma. Oncology 82:197-204
56. Lee H, Herrmann A, Deng JH et al. (2009) Persistently activated Stat3 maintains constitutive NF-kappa B activity in tumors. Cancer Cell 15:283-93
57. Lefebvre J, Muharram G, Leroy C et al. (2013) Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity. Cell Death Dis 4:871
58. Levy C, Khaled M, Fisher DE (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12:406-14
59. Levy C, Khaled M, Iliopoulos D et al. (2010) Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 40:841-9
60. Lister JA, Capper A, Zeng Z et al. (2014) A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Invest Dermatol 134:133-40
61. Liu F, Fu Y, Meyskens FL Jr (2009) MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1/Ref-1. J Invest Dermatol 129:422-31
62. Luo C, Merz PR, Chen Y et al. (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341:240-7
63. Mascarenhas JB, Littlejohn EL, Wolsky RJ et al. (2010) PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37
64. McGill GG, Haq R, Nishimura EK et al. (2006) c-MET expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281:10365-73
65. McGill GG, Horstmann M, Widlund HR et al. (2002) Bcl2 regulation by the melanocytes master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 19:707-18
66. Mills CN, Joshi SS, Niles RM (2009) Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer 8:104
67. Mobley AK, Braeuer RR, Kamiya T et al. (2012) Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev 31:621-32
68. Mohana-Kumaran N, Hill SD, Allen JD et al. (2014) Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res 27:525-39
69. Nachmias B, Ashhab Y, Bucholtz V et al. (2003) Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 63:6340-9
70. Oberoi-Khanuja TK, Karreman C, Larisch S et al. (2012) Role of melanoma inhibitor of apoptosis (ML-IAP), a member of baculoviral IAP repeat (BIR) domain family in the regulation of C-RAF kinase and cell migration. J Biol Chem 287:28445-55
71. Ondrusova L, Vachtenheim J, Reda J et al. (2013) MITF-independent pro-survival role of BRG1-containing SWI/SNF complex in melanoma cells. PLoS One 8:e54110
72. Opdecamp K, Nakayama A, Nguyen MT et al. (1997) Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. Development 124:2377-86
73. Pinner S, Jordan P, Sharrock K et al. (2009) Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 69:7969-77
74. Placzek WJ, Wei J, Kitada S et al. (2010) A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 1:e40
75. Quintana E, Shackleton M, Foster HR et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510-23
76. Raisova M, Bektas M, Wieder T et al. (2000) Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett 473:27-32
77. Saez-Ayala M, Montenegro MF, Sanchez-del-Campo L et al. (2013) Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell 24:1-15
78. Saladi SV, Wong PG, Trivedi AR et al. (2013) BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Pigment Cell Melanoma Res 26:377-91
79. Schepsky A, Bruser K, Gunnarsson GJ et al. (2006) The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol 26:8914-27
80. Segura MF, Hanniford D, Menendez S et al. (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106:1814-9
81. Senft D, Berking C, Graf SA et al. (2012) Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS One 7:e30821
82. Sestakova B, Ondrusova L, Vachtenheim J (2010) Cell cycle inhibitor p21/WAF1/CIP1 as a cofactor of MITF expression in melanoma cells. Pigment Cell Melanoma Res 23:238-51
83. Shah M, Bhoumik A, Goel V et al. (2010) A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 6:e1001258
84. Smith MP, Ferguson J, Arozarena I et al. (2013) Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105:33-46
85. Somasundaram R, Villanueva J, Herlyn M (2012) Intratumoral heterogeneity as a therapy resistance mechanisms: role of melanoma subpopulations. Adv Pharmacol 65:335-59
86. Straussman R, Morikawa T, Shee K et al. (2012) Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4
87. Sturm RA, Fox C, McClenahan P et al. (2014) Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol 134:141-9
88. Syed DN, Afaq F, Maddodi N et al. (2011) Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/b-catenin signaling and decreased Mitf levels. J Invest Dermatol 131:1291-9
89. Sztiller-Sikorska M, Koprowska K, Majchrzak K et al. (2014) Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells. PloS One 9:e90783
90. Thurber AE, Douglas G, Sturm EC et al. (2011) Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30:3036-48
91. Trisciuoglio D, Gabellini C, Desideri M et al. (2010) Bcl-2 regulates HIF-1 alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PloS One 5:e11772
92. Trisciuoglio D, Gabellini C, Desideri M et al. (2011) Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ 18:1024-35
93. Vachtenheim J, Ondrusova L, Borovansky J (2010) SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. Biochem Biophys Res Commun 392:454-9
94. Van Allen EM, Wagle N, Sucker A et al. (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4:94-109
95. Vucic D, Stennicke HR, Pisabarro MT et al. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10:1359-66
96. Wang X, DeFrances MC, Dai Y et al. (2002) A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 9:411-21
97. Wardwell-Ozgo J, Dogruluk T, Gifford A et al. (2014) HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33:1017-26
98. Widlund HR, Horstmann MA, Price ER et al. (2002) β-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158:1079-87
99. Widmer DS, Cheng PF, Eichhoff OM et al. (2012) Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res 25:343-53
100. Widmer DS, Hoek KS, Cheng PF et al. (2013) Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. J Invest Dermatol 133:2436-43
101. Wilson TR, Fridlyand J, Yan Y et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-9
102. Xiao D, Ohlendorf J, Chen Y et al. (2012) Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PloS One 7:e46874
103. Xiao GH, Jeffers M, Bellacosa A et al. (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 98:247-52
104. Yajima I, Kumasaka MY, Thang ND et al. (2011) Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer 2011:730170
105. Yan H, Brouha B, Liu T et al. (2006) Proteolytic cleavage of livin (ML-IAP) in apoptotic melanoma cells potentially mediated by a non-canonical caspase. J Dermatol Sci 43:189-200
106. Yasumoto KI, Takeda K, Saito H et al. (2002) Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J 21:2703-14
107. Yokoyama S, Feige E, Poling LL et al. (2008) Pharmacological suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 21:457-63
108. Yokoyama S, Woods SL, Boyle GM et al. (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99-103
109. Zhao X, Fiske B, Kawakami A et al. (2011) Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun 2:414